ALN-6222 / Alnylam - LARVOL DELTA

Alnylam: New siRNA-targeted weight loss drug initiates Phase I clinical trials. [Google translation] (bydrug.pharmcube.com) - "The Phase I clinical trial plans to enroll 88 obese participants and is expected to be completed by the end of 2027. ALN-6222 is Alnylam's second weight-loss siRNA drug to enter clinical trials."

Trial status • Obesity